中国医疗健康行业投融资呈现出典型的“结构性修复”特征，市场在总量回暖的同时，内部逻辑正经历深刻重塑。推动这轮投融资结构性变化的关键驱动力来自政策与产业两端。政策层面，医保谈判对“真创新”的支持、商业健康险作为新支付方的加速入场，以及“十五五”规划将医药行业列为新兴支柱产业，都为行业注入了明确的长期信心。产业层面，中国创新药通过对外授权和国际化合作，其全球竞争力已得到实质性验证，不仅带来了丰厚现金回流，也打开了更广阔的估值想象空间。
全球领先的新经济产业第三方数据挖掘和分析机构iiMedia Research（艾媒咨询）最新发布的《2026年中国医疗健康行业半年投融资情况》数据显示，2026年上半年，中国医疗健康行业投融资事件总计436起，金额达683.09亿人民币。相较于前几年，事件数量有所下滑，但单笔融资规模显著提升。艾媒咨询分析师认为，这一变化与人工智能、新能源及生物医药等硬科技赛道集中吸金密切相关，资本向头部项目聚拢推高了平均金额。投融资波动主要受宏观政策导向影响，如国家基金对关键领域加大支持、退出渠道收紧导致早期项目融资难度上升等。市场表现上，行业整合加速，高估值企业更受青睐，预计未来资金将进一步向技术壁垒高的领域集中，推动产业升级与结构优化。
总体而言，中国医疗健康行业优质资产的融资效率明显提升，普通项目的融资难度并未同步下降。未来，行业最重要的竞争力将不再是单一的资金获取能力，而是能够整合科研、临床、制造、注册、支付和国际商业化的综合组织能力。
Investment and financing in China’s healthcare industry are exhibiting typical characteristics of “structural recovery”; while the market is rebounding in overall volume, its internal dynamics are undergoing a profound reshaping. The key drivers behind this round of structural changes in investment and financing stem from both policy and industry perspectives. On the policy front, support for “genuine innovation” through medical insurance negotiations, the accelerated entry of commercial health insurance as a new payer, and the designation of the pharmaceutical industry as an emerging pillar industry in the 15th Five-Year Plan have all injected clear, long-term confidence into the sector. On the industry front, the global competitiveness of China’s innovative drugs has been substantially validated through licensing agreements and international collaborations, which have not only generated substantial cash inflows but also opened up broader prospects for valuation growth.
According to the latest report,“2026 China Healthcare Industry Mid-Year Investment and Financing Overview”released by iiMedia Research—a leading global third-party data mining and analysis firm specializing in the new economy—there were a total of 436 investment and financing deals in China’s healthcare industry during the first half of 2026, with a total value of 68.309 billion RMB. While the number of deals has declined compared to previous years, the average deal size has increased significantly. iiMedia Research analysts believe this shift is closely linked to the concentrated capital inflows into “hard tech” sectors such as artificial intelligence, new energy, and biopharmaceuticals; the concentration of capital on leading projects has driven up the average deal size. Fluctuations in investment and financing are primarily influenced by macroeconomic policy trends, such as increased support from national funds for key sectors and tighter exit channels, which have made it more difficult for early-stage projects to secure funding. In terms of market performance, industry consolidation is accelerating, and companies with high valuations are gaining favor. It is expected that capital will further concentrate in sectors with high technological barriers, driving industrial upgrading and structural optimization.
Overall, the financing efficiency of high-quality assets in China’s healthcare industry has improved significantly, while the difficulty of securing funding for ordinary projects has not decreased accordingly. In the future, the industry’s most important competitive advantage will no longer be the ability to secure funding alone, but rather the comprehensive organizational capability to integrate research, clinical trials, manufacturing, regulatory approval, payment systems, and international commercialization.
中国医疗健康2026上半年投融资趋势
数据显示，2026年上半年投融资事件总计436起，金额达683.09亿人民币。相较于前几年，事件数量有所下滑，但单笔融资规模显著提升，市场呈现“少而精”特征。艾媒咨询分析师认为，这一变化与人工智能、新能源及生物医药等硬科技赛道集中吸金密切相关，资本向头部项目聚拢推高了平均金额。投融资波动主要受宏观政策导向影响，如国家基金对关键领域加大支持、退出渠道收紧导致早期项目融资难度上升等。市场表现上，行业整合加速，高估值企业更受青睐，预计未来资金将进一步向技术壁垒高的领域集中，推动产业升级与结构优化。
2026年1-6月全球投融资概况
数据显示，2026年1-6月投融资事件总数从1月的100起波动下行至5月的51起，6月小幅回升至63起，整体呈下降趋势；金额方面，1-3月稳定在112.00-115.00亿人民币区间，4月骤降至90.94亿人民币后反弹，6月创下142.37亿人民币峰值。艾媒咨询分析师认为，一季度春节前后投融资活跃度较高；4月事件数量与金额同步下滑，或因年报披露期机构策略趋于谨慎，叠加医疗健康等行业政策调整期，市场观望情绪浓厚；5-6月金额显著回升，资本向少数大额项目集中，单笔融资规模扩大，反映行业整合与头部企业融资加速。
医疗健康主题各赛道投融资金额及数量
数据显示，制药赛道以382.70亿元融资额和140起事件占据大比重，医疗器械、生物技术紧随其后，三者合计占总金额近85%，集中度较高。艾媒咨询分析师认为，制药赛道的高额融资反映创新药研发仍为资本重仓领域；医疗器械和生物技术的活跃度则与热度强相关，事件数与金额基本匹配；专科医疗和寻医诊疗虽然事件少但单笔金额较高，显示资本向成熟商业模式集中；健康保健、医疗信息化等赛道融资分散，反映资本偏好早期布局但加仓谨慎。整体投资趋势正向创新领域和技术驱动倾斜，受产业周期和政策环境影响较深。
医疗健康主题投融资轮次分布
数据显示，2026上半年医疗健康融资轮次分布中，IPO及后续融资占据大比重，反映头部企业密集登陆公开市场；C轮、A轮、B轮等成长期轮次体量庞大，显示资本对已验证项目重仓跟进；而种子轮、Pre-A轮等早期阶段虽金额有限但仍保持活跃，说明行业创新源头未被冷落。战略投资与基石轮频繁出现，凸显产业资本和上市护航角色的重要性；新三板相关融资归零，表明该板块已彻底边缘化。艾媒咨询分析师认为，行业正从“广撒网”转向“精聚焦”，资本加速向中后期头部项目集中，早期投资更趋谨慎，但并未完全收缩，市场正处于理性分化与结构性调整的关键阶段。
医疗健康主题融资金额TOP10企业
数据显示，医疗健康主题融资金额TOP10企业中，前三名分别为人福医药（35.00亿人民币）、美诺华（21.09亿人民币）、济煜医药(20.00亿人民币)，融资金额合计占TOP10总融资金额的26.2%。艾媒咨询分析师认为，头部企业融资集中度较高，但金额分布相对均衡，表明资本对医疗健康领域采取多点布局策略。高融资额企业多聚焦创新药、生物技术及原料药赛道，反映资本市场偏好具有技术壁垒和临床未满足需求的方向。融资规模多集中在亿级，显示企业多处于研发中后期或商业化扩张阶段，如人福医药、美诺华为成熟企业融资用于产能升级，而天辰生物、瑞博生物等新兴企业则靠大额资金推动管线进展。
医疗健康主题投资活跃度TOP10机构
数据显示，医疗健康主题投资活跃度TOP10机构中，前三名分别为：启明创投12起、倚锋资本12起、顺禧基金11起，合计占TOP10总投资次数的8.2%，体现一定集中度，但分布较为均匀。艾媒咨询分析师认为，活跃机构中既有启明创投、倚锋资本等高频投资者，展示广泛撒网策略；也有奥博资本等10笔总金额高达47.8亿人民币的精准重注，反映风险偏好分化。顺禧基金、新氧等偏向早期及产业布局，而深创投、元禾控股等国资背景机构注重稳健性。整体热点聚焦于创新药、医疗器械及数字医疗，头部机构更倾向布局早中期项目以抢占赛道先机，后续轮次则强化资本支持。
热门跟贴